Publication: SARS-CoV-2 infection in a pediatrics STAT1 GOF patient under Ruxolitinib therapy-a matter of balance?
dc.contributor.author | Guisad-Hernandez, Paloma | |
dc.contributor.author | Blanco-Lobo, Pilar | |
dc.contributor.author | Villaoslada, Isabel | |
dc.contributor.author | de-Felipe, Beatriz | |
dc.contributor.author | Lucena, Jose M | |
dc.contributor.author | Martin-Gutierrez, Guillermo | |
dc.contributor.author | Castro, María Jose | |
dc.contributor.author | Gutierrez-Valencia, Alicia | |
dc.contributor.author | Sanchez-Codez, Maria Isabel | |
dc.contributor.author | Gaboli, Mirella | |
dc.contributor.author | Neth, Olaf | |
dc.contributor.author | Olbrich, Peter | |
dc.date.accessioned | 2023-02-09T11:40:18Z | |
dc.date.available | 2023-02-09T11:40:18Z | |
dc.date.issued | 2021-06-09 | |
dc.description.abstract | Recently, 94 inborn errors of immunity (IEI) patients suffering from COVID-19 have been described, overall demonstrating a mild phenotype [1] although more severe disease manifestations have been suggested for patients with alterations in the interferon (IFN) signaling pathway, including auto-antibodies against type I IFN [2]. Patients with STAT1 GOF mutations show a complex and often severe phenotype, combining an increased susceptibility of fungal, (myco-) bacterial and viral infections as well as autoimmune and autoinflammatory manifestations [3]. Characteristically, in response to type I and type II IFN stimulation, these patients show STAT1 hyperphosphorylation [3, 4]. Whether in the context of SARS-CoV-2 infection, the hyperactivation of the IFN-JAK1/2-STAT1 pathway would be protective (antiviral effect) or deleterious (hyperinflammation) is unclear. Ruxolitinib (a selective JAK1/2 inhibitor) has been successfully used in STAT1 GOF patients controlling many disease manifestations [5] and also resulted in improved pulmonary function and faster recovery from lymphopenia in previously healthy individuals suffering from severe COVID-19 | |
dc.description.version | Si | |
dc.identifier.citation | Guisado Hernández P, Blanco Lobo P, Villaoslada I, de Felipe B, Lucena JM, Martín Gutierrez G, et al. SARS-CoV-2 infection in a pediatrics STAT1 GOF patient under Ruxolitinib therapy-a matter of balance? J Clin Immunol. 2021 Oct;41(7):1502-1506. | |
dc.identifier.doi | 10.1007/s10875-021-01081-9 | |
dc.identifier.essn | 1573-2592 | |
dc.identifier.pmc | PMC8189704 | |
dc.identifier.pmid | 34109505 | |
dc.identifier.pubmedURL | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8189704/pdf | |
dc.identifier.unpaywallURL | https://link.springer.com/content/pdf/10.1007/s10875-021-01081-9.pdf | |
dc.identifier.uri | http://hdl.handle.net/10668/17982 | |
dc.issue.number | 7 | |
dc.journal.title | Journal of clinical immunology | |
dc.journal.titleabbreviation | J Clin Immunol | |
dc.language.iso | en | |
dc.organization | Hospital Universitario Puerta del Mar | |
dc.organization | Instituto de Biomedicina de Sevilla-IBIS | |
dc.organization | Hospital Universitario Virgen del Rocío | |
dc.page.number | 1502-1506 | |
dc.provenance | Realizada la curación de contenido 10/07/2025. | |
dc.publisher | Springer New York LLC | |
dc.pubmedtype | Case Reports | |
dc.pubmedtype | Letter | |
dc.pubmedtype | Research Support, Non-U.S. Gov't | |
dc.relation.publisherversion | https://doi.org/10.1007/s10875-021-01081-9 | |
dc.rights.accessRights | Restricted Access | |
dc.subject | COVID-19 | |
dc.subject | Interferon-Stimulated Gene Factor 3 | |
dc.subject | Pyrazoles | |
dc.subject | COVID-19 Drug Treatment | |
dc.subject.decs | COVID-19 | |
dc.subject.decs | Mutación | |
dc.subject.decs | SARS-CoV-2 | |
dc.subject.decs | Linfopenia | |
dc.subject.decs | Virosis | |
dc.subject.decs | Interferones | |
dc.subject.decs | Insuficiencia multiorgánica | |
dc.subject.decs | Antineoplásicos inmunológicos | |
dc.subject.decs | Diabetes mellitus tipo 2 | |
dc.subject.mesh | Child | |
dc.subject.mesh | Female | |
dc.subject.mesh | Humans | |
dc.subject.mesh | Janus Kinases | |
dc.subject.mesh | Mutation | |
dc.subject.mesh | Nitriles | |
dc.subject.mesh | Pyrimidines | |
dc.subject.mesh | SARS-CoV-2 | |
dc.subject.mesh | Severity of Illness Index | |
dc.title | SARS-CoV-2 infection in a pediatrics STAT1 GOF patient under Ruxolitinib therapy-a matter of balance? | |
dc.type | letter to the editor | |
dc.type.hasVersion | VoR | |
dc.volume.number | 41 | |
dspace.entity.type | Publication |
Files
Original bundle
1 - 1 of 1
No Thumbnail Available
- Name:
- RISalud_Accesorestringido.pdf
- Size:
- 93.39 KB
- Format:
- Adobe Portable Document Format